Medicine:Activation syndrome
Activation syndrome is a form of stimulation (sometimes suicidal) or agitation that has been observed in association with some psychoactive drugs.[1] A causative role has not been established.[2] Pfizer has denied that sertraline can cause such effects.[3][4]
Treatment
Serotonin reuptake inhibitors (SSRI) have been associated with a state of restlessness, lability, agitation, and anxiety termed "activation syndrome". In some people, this state change can increase suicidal tendencies, especially in those under age 25 and during the initial weeks of treatment.[2] SSRI-induced activation syndrome is well-accepted by clinicians.[5] It is unclear whether jitteriness/anxiety syndrome predicts either good or poor prognosis (level D). [6] Activation syndrome resolves within hours of discontinuing the serotonergic agent and initiating care. However, resolution of symptoms may be slightly longer in those taking medications with longer half-lives, such as monoamine oxidase inhibitors (MAOIs).[citation needed]
References
- ↑ "Recent regulatory 2006". http://www.breggin.com/recentregulatory.pbreggin.2006.pdf.
- ↑ 2.0 2.1 "www.accessdata.fda.gov". http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018936s102lbl.pdf.
- ↑ "Pfizer letter to Healy". http://www.healyprozac.com/AcademicStalking/Post%203%20-%20Pfizer%20letter%20re%20Healy.pdf.
- ↑ "Archived copy". http://www.ahrp.org/ethical/HealyResponseToPfizer.pdf.
- ↑ "Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile". Child Youth Care Forum 39 (2): 113–124. 2010. doi:10.1007/s10566-010-9095-5. PMID 20473344.
- ↑ Lindsey I. Sinclair; David M. Christmas; Sean D. Hood; John P. Potokar; Andrea Robertson; Andrew Isaac; Shrikant Srivastava; David J. Nutt et al. (2009). "Antidepressant-inducedjitteriness/anxiety syndrome:systematicreview". The British Journal of Psychiatry 194 (6): 483–490. doi:10.1192/bjp.bp.107.048371. PMID 19478285.
 |  |
